Medicalgorithmics S.A. — Share Issue/Capital Change 2024

Sep 16, 2024

Report Content Admissionand conditional introduction of the Company's series J shares to tradingon the main market of the WSE. Setting the date of the first listing ofthe Company's series J shares after their assimilation with sharestraded on the main market.

CurrentReport No.: 19/2024

Date:September 13, 2024

LegalBasis: Article 56(1)(2) of the Act on Public Offering - Current andPeriodic Information

TheManagement Board of Medicalgorithmics S.A. with its registered office inWarsaw (the "Issuer", the "Company"),hereby announces that on 13 September 2024 it received information onthe adoption of Resolution No. 1134/2024 of the Management Board of theWarsaw Stock Exchange S.A. ("WSE") on the admission andintroduction to exchange trading on the WSE Main Market of series Jbearer ordinary shares of Medicalgorithmics S.A. (the "Resolution").

Pursuantto the Resolution,1,194,331(one million one hundred and ninety-fourthousand three hundred and thirty-one) series J bearer common shares ofthe Company carrying ISIN codePLMDCLG00056(the "Shares"), with a nominal value of 0.10 (ten groszy)each, were admitted to trading on the main market.

Pursuantto the Resolution, the Shares will be listed on the main market as ofSeptember 20, 2024, subject to the assimilation of the Shares by theNational Securities Depository (Krajowy Depozyt Papierów WartościowychS.A.) on September 20, 2024, with the Company's shares traded on thestock exchange, under the code PLMDCLG00015. The Company will announcethe assimilation of the Shares in a separate current report.

TheCompany reminds that the Shares were issued in accordance with theResolution No. 4 of the Company's Extraordinary General Meeting ofOctober 28, 2022 Increase of the Company's share capital through issueof series I, J, K and L shares; waiver of existing shareholders'subscription rights; private subscription offer for a designated entity;and change of Article 5 (1) and (2) of the Articles of Association. Theshares were registered with the National Securities Depository on March7, 2023, as the Company announced in current report number 8/2023 onMarch 8, 2023.

TheCompany reminds that in the current report No. 55/2022 it informed onOctober 1, 2022, that 4,976,384 Shares were acquired by Biofund CapitalManagement LLC with its registered office in Miami (USA). These sharesare to be introduced to trading under the applicable exceptions to theobligation to prepare an issue prospectus, and the planned date ofintroducing all these shares to trading has been set at the end of 2026.